

Referenser

1. Läkemedel – statistik från år 2009. Socialstyrelsen 2010.
2. Ray KK, Seshasai SR, Erquo S et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. *Arch Intern Med* 2010 Jun 28; 170(12):1924-31
3. Taylor F, Ward K, Moore TH et al. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2011 Jan 19;1:CD004816
4. Melander A, Lindeberg G. Kan läkemedel förebygga ohälsa? NEPI-rapport, Apotekarsocieteten 2004
5. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med*. 1995;333:1301-1307
6. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/ TexCAPS. *JAMA* 1998;279:1615-22
7. Håkansson Jan. Stärkt stöd för statinbehandling som sekundärprevention. Tveksam evidens för behandling mot allt lägre kolesterolvärden. *Läkartidningen* 2010(11) 1234-5
8. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. *JAMA*. 1987 Apr 24;257(16):2176-80
9. Castelli WP, Wilson PW, Levy D, Anderson K. Cardiovascular risk factors in the elderly. *Am J Cardiol*. 1989 May 2;63(16):12H-19H.
10. Ramsden et al: Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. *BMJ* 2013;346:e8707
11. Greene JA. Prescribing by numbers. Drugs and the definition of disease, John Hopkins University Press 2006 ISBN 0-8018-8477-2, p 181
12. Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC Jr, Dai D, Hernandez A, Fonarow GC. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. *Am Heart J*. 2009 Jan;157(1):111-117.e2. Epub 2008 Oct 22.
13. Keys A, Aravanis C, Blackburn H et al. Probability of middle-aged men developing coronary heart disease in five years. *Circulation*. 1972 Apr;45(4):815-28
14. Werkö L. End of the road for the diet-heart theory? *Scand Cardiovasc J*. 2008 Aug;42(4):250-5. R
15. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet*. 2007 Dec 1;370(9602):1829-3
16. Rudnichi A, Safar M, Asmar R, Guize L, Benetos A. Prevalence of cardiovascular risk factors in a French population. *J Hypertens* 1998; 16 (suppl): S85-90.
17. <http://image.thelancet.com/extras/01art8300webappendixA.pdf>
18. Siegel D, Kuller L, Lazarus NB, Black D, Feigal D, Hughes G, et al. Predictors of cardiovascular events and mortality in the Systolic Hypertension in the Elderly Program pilot project. *Am J Epidemiol* 1987;126:385-99.
19. Dagenais GR, Ahmed Z, Robitaille NM, Gingras S, Lupien PJ, Christen A, et al. Total and coronary heart disease mortality in relation to major risk factors – Quebec cardiovascular study. *Can J Cardiol* 1990;6:59-65.
20. Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR. High blood cholesterol in elderly men and the excess risk for coronary heart disease. *Ann Intern Med*. 1990;113:916-20.
21. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. *Arch Intern Med*. 1993;153:2209-16.
22. Shestov DB, Deev AD, Klimov AN, Davis CE, Tyroler HA. Increased risk of coronary heart disease death in men with low total and low-density lipoprotein cholesterol in the Russian Lipid Research Clinics Prevalence Follow-up Study. *Circulation*. 1993;88:846-53.
23. Corti MC, Guralnik JM, Salive ME, Harris T, Field TS, Wallace RB, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. *JAMA*. 1995;274:539-44.
24. Simons LA, Friedlander Y, McCallum J, Simons J. Risk factors for coronary heart disease in the prospective Dubbo Study of Australian elderly. *Atherosclerosis*. 1995;117:107-18.
25. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. *Lancet*. 1997;350:1119-23.
26. Daviglius ML, Stamler J, Pirzada A, Yan LL, Garside DB, Liu K, et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. *JAMA*. 2004;292:1588-92.
27. Ulmer H, Kelleher C, Diem G, Concin H. Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. *J Womens Health*. 2004;13:41-53.
28. Pearte CA, Furberg CD, O'Meara ES, Psaty BM, Kuller L, Powe NR, Manolio T. Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the Cardiovascular Health Study. *Circulation*. 2006;113:2177-85.
29. Zoe Mullan. Personlig kommunikation 2010-10-01
30. Lestavel S, Fruchart JC. Lipoprotein receptors. *Cell Mol Biol (Noisy-le-grand)*. 1994 Jun;40(4):461-81.
31. Schroeder F, Gallegos A, Atshaves BP et al. Recent advances in membrane microdomains: Rafts, caveolae and intracellular cholesterol trafficking. *Exp Biol Med* 2001; 226:873-90
32. Dart AM, Chin-Dusting JP. Lipids and the endothelium. *J Lipid Res*. 2004 Jun;45(6):993-1007. Epub 2004 Apr 1.
33. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. *Sci Signal*. 2009 May 26;2(72):re3
34. Adachi H, Tsujimoto M. Endothelial scavenger receptors. *Prog Lipid Res*. 2006 Sep;45(5):379-404. Epub 2006 Apr 19.
35. de Villiers WJ, Smart EJ. Macrophage scavenger receptors and foam cell formation. *J Leukoc Biol*. 1999 Nov;66(5):740-6.
36. Navab M, Ananthramiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. *Cardiovasc Res*. 1999 Aug 1;43(2):308-22.
37. Attie AD, Krauss RM, Gray-Keller MP, Brownlie A, Miyazaki M, Kastelein JJ, Lusis AJ, Stalenhoef AF, Stoehr JP, Hayden MR, Ntambi JM. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. *J Lipid Res*. 2002 Nov;43(11):1899-907.
38. Dreon DM, Fernstrom HA, Williams PT, Krauss RM. A very low-fat diet is not associated with improved lipoprotein profiles in men with a predominance of large, low-density lipoproteins. *Am J Clin Nutr*. 1999 Mar;69(3):411-8.
39. Dreon DM, Fernstrom HA, Campos H, Blanche P, Williams PT, Krauss RM. Change in dietary saturated fat intake is correlated with change in mass of large low-density-lipoprotein particles in men. *Am J Clin Nutr*. 1998 May;67(5):828-36.
40. Chancharne L, Théron P, Nigon F, Lepage S, Couturier M, Chapman MJ. Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL. *Arterioscler Thromb Vasc Biol*. 1999 Mar;19(3):810-20.
41. Younis N, Charlton-Menys V, Sharma R, Soran H, Durrington PN. Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. *Atherosclerosis*. 2009 Jan;202(1):162-8.
42. Knoll AH. A new molecular window on early life. *Science*. 1999 Aug 13;285(5430):1025-6.
43. Miao L, Nielsen M, Thewalt J, Ipsen JH, Bloom M, Zuckermann MJ, Mouritsen OG. From lanosterol to cholesterol: structural evolution and differential effects on lipid bilayers. *Biophys J*. 2002 Mar;82(3):1429-44.
44. Levitan I, Fang Y, Rosenhouse-Dantsker A, Romanenko V. Cholesterol and Ion Channels. *Subcell Biochem* 2010; 51:509-549
45. Martinez-Seara H, Róg T, Pasenkiewicz-Gierula M et al. Interplay of unsaturated phospholipids and cholesterol in membranes: effect of the double-bond position. *Biophys J* 2008; Oct;95(7):3295-305
46. Grundy SM, Ahrens EH. The effects of unsaturated dietary fats on absorption, excretion, synthesis and distribution of cholesterol in man. *J Clin Invest* 1970; 49:1135-52
47. Adams, C. M., Goldstein, J. L., and Brown, M. S. (2003). Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. *Proc. Natl. Acad. Sci. USA* 100, 10647-10652.
48. Ridsdale A, Denis M, Gougeon PY et al. Cholesterol is required for efficient ER-to-Golgi transport of secretory membrane proteins. *Mol Biol Cell* 2006; 107:1643-43
49. Vikman J, Jimenez-Feltström J, Nyman P, Thelin J, Eliasson L. Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. *FASEB J*. 2009 Jan;23(1):58-67
50. Porter FD, Herman GE. Malformation syndromes caused by disorders of cholesterol synthesis. *J Lipid Res*. 2011 Jan;52(1):6-34.
51. Wasser CR, Ertunc M, Liu X, Kavalali ET. Cholesterol-dependent balance between evoked and spontaneous synaptic vesicle recycling. *J Physiol*. 2007 Mar 1;579(Pt 2):413-29
52. Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol

- serum levels have a prolonged survival in amyotrophic lateral sclerosis. *J Neurol*. 2010 Dec 3. [Epub ahead of print]
53. Salemi G, Gueli MC, Vitale F, Battaglieri F, Guglielmini E, Ragonese P, Trentacosti A, Massenti MF, Savettieri G, Bono A. Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. *Lipids Health Dis*. 2010 Feb 18;9:19
54. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. *J Clin Psychiatry*. 2009 Jul;70(7):997-1000
55. Troisi A. Low cholesterol is a risk factor for attentional impulsivity in patients with mood symptoms. *Psychiatry Res*. 2010 Nov 27
56. Jokinen J, Nordström AL, Nordström P. Cholesterol, CSF 5-HIAA, violence and intent in suicidal men. *Psychiatry Res*. 2010 Jun 30;178(1):217-9. Epub 2010 May 8.
57. Martínez-Carpio PA, Barba J, Bedoya-Del Campillo A. Relation between cholesterol levels and neuropsychiatric disorders. *Rev Neurol*. 2009 Mar 15;48(5):261-4.
58. Han R. Plasma lipoproteins are important components of the immune system. *Microbiol Immunol*. 2010 Apr;54(4):246-53.
59. Do TQ, Moshkani S, Castillo P, Anunta S, Pogosyan A, Cheung A, Marbois B, Faull KF, Ernst W, Chiang SM, Fujii G, Clarke CF, Foster K, Porter E. Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid. *J Immunol*. 2008 Sep 15;181(6):4177-87.
60. Ravnskov U, McCully KS. Infections may be causal in the pathogenesis of atherosclerosis. *Am J Med Sci*. 2012 Nov;344(5):391-4.
61. Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, Richards AM. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. *J Am Coll Cardiol*. 2008 Oct 28;52(18):1435-41.
62. Al-Mallah M, Hatahet H, Cavalcante J, Khanal S. Low admission LDL-cholesterol is associated with increased 3-year all-cause mortality in patients with non ST segment elevation myocardial infarction. *Cardiol J*. 2009;16:227-33
63. Elkeles RS, Godsland IF, Rubens MB, Feher MD, Nugara F, Flather MD. The progress of coronary heart disease in Type 2 diabetes as measured by coronary calcium score from electron beam computed tomography (EBCT): the PREDICT study. *Atherosclerosis*. 2008 Apr;197(2):777-83. Epub 2007 Oct 24.
64. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. *BMJ*. 2010 May 20;340:c2197. doi: 10.1136/bmj.c2197.
65. Do C, Huyghe E, Lapeyre-Mestre M, Montastruc JL, Bagheri H. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. *Drug Saf*. 2009;32(7):591-7
66. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383-1389
67. De Lorgeril M, Salen P. Recent cholesterol-lowering drug trials: New data, new questions. *J Lipid Nutr*. Vol.19, No.1 (2010) 65-92
68. P.O. Bonetti, L.O. Lerman, C. Napoli, A. Lerman. Statin effects beyond lipid lowering—are they clinically relevant? *European Heart Journal* 2003 24, 225–24
69. Shibata T, Tamura M, Kabashima N et al. Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells. *Life Sci* 2009; May 22;84(21-22):725-31